Treg cell abnormality and its potential treatments in patients with primary immune thrombocytopenia

4Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Primary immune thrombocytopenia (ITP) is an autoimmune heterogeneous disorder. T regulatory cells (Treg), play an important role in the pathogenesis of the disease. Numerical and functional disorders of Treg cells were both demonstrated in ITP. Thymocyte output decrease and instability of Treg cells contributed to the lower count of the cells. Several immune deregulatory defects of Treg cells further led to the disease's onset. Restoring Treg cells might have a therapeutic effect on ITP. New options focusing on increasing the number, or enhancing the immunomodulating function of Treg cells was reviewed in this manuscript.

Cite

CITATION STYLE

APA

Ji, L., & Cheng, Y. (2022, September 1). Treg cell abnormality and its potential treatments in patients with primary immune thrombocytopenia. Clinical and Translational Discovery. Blackwell Publishing. https://doi.org/10.1002/ctd2.77

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free